StockData
Lantern Pharma Inc. logo

Lantern Pharma Inc. (LTRN) stock

LTRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 17, 2026Score 5/30
$0.36−0.02 (-6.17%)

Close on Nov 17, 2026Market cap $4.67MP/E –Yield –

Lantern Pharma r&d expenses

Research and development expenses are spending on new products and technology.

Lantern Pharma's R&D Expenses for the twelve months ending Sep 30, 2026 was $7.83M, down 40.0% year over year. For fiscal 2025 it was $11.51M, down 28.6% from the year before. The highest annual figure on record is $16.13M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$11.51M-28.6%
FY2024Dec 31, 2024$16.13M+35.6%
FY2023Dec 31, 2023$11.89M+38.3%
FY2022Dec 31, 2022$8.60M+13.6%
FY2021Dec 31, 2021$7.57M+237.5%
FY2020Dec 31, 2020$2.24M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.57M-35.6%
Q2 FY2026Jun 30, 2026$1.79M-41.6%
Q1 FY2026Mar 31, 2026$1.72M-47.2%
Q4 FY2025Dec 31, 2025$2.74M-35.7%
Q3 FY2025Sep 30, 2025$2.44M-34.4%
Q2 FY2025Jun 30, 2025$3.07M-21.1%
Q1 FY2025Mar 31, 2025$3.26M-23.2%
Q4 FY2024Dec 31, 2024$4.27M+19.5%
Q3 FY2024Sep 30, 2024$3.72M+68.2%
Q2 FY2024Jun 30, 2024$3.89M+9.3%
Q1 FY2024Mar 31, 2024$4.25M+66.5%
Q4 FY2023Dec 31, 2023$3.57M+58.7%
Q3 FY2023Sep 30, 2023$2.21M+214.7%
Q2 FY2023Jun 30, 2023$3.56M+19.1%
Q1 FY2023Mar 31, 2023$2.55M-4.0%
Q4 FY2022Dec 31, 2022$2.25M+4.1%
Q3 FY2022Sep 30, 2022$702.30K-76.3%
Q2 FY2022Jun 30, 2022$2.99M+156.6%
Q1 FY2022Mar 31, 2022$2.66M+108.0%
Q4 FY2021Dec 31, 2021$2.16M+60.4%
Q3 FY2021Sep 30, 2021$2.96M+393.4%
Q2 FY2021Jun 30, 2021$1.16M+641.9%
Q1 FY2021Mar 31, 2021$1.28M+832.9%
Q4 FY2020Dec 31, 2020$1.35M–
Q3 FY2020Sep 30, 2020$600.77K–
Q2 FY2020Jun 30, 2020$157.02K–
Q1 FY2020Mar 31, 2020$137.10K–

More Lantern Pharma figures

See a number that looks wrong?